<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.1" specific-use="sps-1.9" article-type="letter" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">TtLjWnXyp4LtGpKhgBqdyym</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2025000500903</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20250159</article-id>
      <article-id pub-id-type="other">00903</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Carta ao Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Como Avaliar a Condu&#231;&#227;o El&#233;trica Prejudicada do Cora&#231;&#227;o Direito em Pacientes com Hipertens&#227;o Arterial Pulmonar?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kataoka</surname>
            <given-names>Naoya</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-7294-7637</contrib-id>
          <name>
            <surname>Imamura</surname>
            <given-names>Teruhiko</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <aff id="aff1">
          <label>1</label>
          <institution content-type="orgname">Universidade de Toyama</institution>
          <institution content-type="orgdiv1">Segundo Departamento de Medicina Interna</institution>
          <addr-line>
            <named-content content-type="city">Toyama</named-content>
          </addr-line>
          <country country="JP">Jap&#227;o</country>
          <institution content-type="original">Segundo Departamento de Medicina Interna, Universidade de Toyama, Toyama &#8211; Jap&#227;o</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1"><label>Correspond&#234;ncia:</label><bold>Teruhiko Imamura &#8226;</bold> Second Department of Internal Medicine, University of Toyama, 2630, Sugitani Toyama, <postal-code>930-0194</postal-code> &#8211; Jap&#227;o E-mail: <email>te.imamu@gmail.com</email></corresp>
      </author-notes>
      <pub-date publication-format="electronic" date-type="pub">
        <day>20</day>
        <month>06</month>
        <year>2025</year>
      </pub-date>
      <pub-date publication-format="electronic" date-type="collection">
        <year>2025</year>
      </pub-date>
      <volume>122</volume>
      <issue>05</issue>
      <elocation-id>e20250159</elocation-id>
      <history>
        <date date-type="received">
          <day>03</day>
          <month>03</month>
          <year>2025</year>
        </date>
        <date date-type="rev-recd">
          <day>26</day>
          <month>03</month>
          <year>2025</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>03</month>
          <year>2025</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xml:lang="en" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave</title>
        <kwd>Eletrocardiografia</kwd>
        <kwd>Insufici&#234;ncia Card&#237;aca</kwd>
        <kwd>Bloqueio de Ramo</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="4"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>Ao editor</bold>
    </p>
    <p>A identifica&#231;&#227;o de uma modalidade ideal para monitorar a gravidade da hipertens&#227;o arterial pulmonar (HAP) continua sendo imperativa. Os autores demonstraram que um intervalo RS prolongado no eletrocardiograma foi associado a desfechos cl&#237;nicos adversos nesta coorte, sob a hip&#243;tese de que a condu&#231;&#227;o el&#233;trica do cora&#231;&#227;o direito est&#225; comprometida em pacientes com HAP grave.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> No entanto, v&#225;rias preocupa&#231;&#245;es merecem considera&#231;&#227;o.</p>
    <p>O intervalo RS foi medido nas deriva&#231;&#245;es inferolaterais, especificamente V5 e V6.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> No entanto, as informa&#231;&#245;es do ventr&#237;culo direito s&#227;o convencionalmente derivadas das deriva&#231;&#245;es precordiais direitas, como V1 e V2. Em casos de bloqueio do ramo direito, uma onda S proeminente nas deriva&#231;&#245;es inferolaterais &#233; uma caracter&#237;stica. Um intervalo RS prolongado nessas deriva&#231;&#245;es pode refletir uma onda R dominante nas deriva&#231;&#245;es precordiais direitas. Estudos anteriores identificaram uma amplitude elevada da onda R na deriva&#231;&#227;o V1 como um marcador progn&#243;stico em pacientes com HAP.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Observa&#231;&#245;es compar&#225;veis foram feitas na s&#237;ndrome de Brugada, onde a disfun&#231;&#227;o ventricular direita predomina.<sup><xref ref-type="bibr" rid="B3">3</xref></sup> A incorpora&#231;&#227;o das caracter&#237;sticas da deriva&#231;&#227;o precordial direita pode aumentar a robustez dos achados dos autores.</p>
    <p>Al&#233;m disso, o comportamento longitudinal do intervalo RS, particularmente sua trajet&#243;ria em resposta a redu&#231;&#245;es na press&#227;o da art&#233;ria pulmonar durante interven&#231;&#245;es terap&#234;uticas, justifica uma explora&#231;&#227;o mais aprofundada.</p>
    <p>Poss&#237;veis fatores de confus&#227;o n&#227;o considerados na an&#225;lise podem ter influenciado os resultados. Dada a longa dura&#231;&#227;o do estudo, de 2010 a 2022,<sup><xref ref-type="bibr" rid="B1">1</xref></sup> o cen&#225;rio terap&#234;utico para HAP provavelmente evoluiu, com mudan&#231;as nos regimes de medica&#231;&#227;o. Al&#233;m disso, as respostas dos pacientes ao tratamento s&#227;o significativamente moduladas por fatores gen&#233;ticos, como muta&#231;&#245;es no gene BMPR2.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Abordar essas vari&#225;veis pode proporcionar uma compreens&#227;o mais abrangente da rela&#231;&#227;o entre o prolongamento do intervalo RS e os desfechos cl&#237;nicos na HAP.</p>
  </body>
  <back>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koyun</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sahin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yilmaz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dindas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cerik</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Koyun</surname>
              <given-names>GB</given-names>
            </name>
          </person-group>
          <article-title>Electrocardiographic Prognostic Marker in Pulmonary Arterial Hypertension: RS Time</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2024</year>
          <volume>121</volume>
          <issue>9</issue>
          <elocation-id>e20240083</elocation-id>
          <pub-id pub-id-type="doi">10.36660/abc.20240083</pub-id>
        </element-citation>
        <mixed-citation>1 Koyun E, Sahin A, Yilmaz A, Dindas F, Cerik IB, Koyun GB. Electrocardiographic Prognostic Marker in Pulmonary Arterial Hypertension: RS Time. Arq Bras Cardiol. 2024;121(9):e20240083. doi: 10.36660/abc.20240083.</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Change in R Wave in Lead V1 Predicts Survival of Patients with Pulmonary Arterial Hypertension</article-title>
          <source>Pulm Circ</source>
          <year>2018</year>
          <volume>8</volume>
          <issue>2</issue>
          <fpage>2045894018776496</fpage>
          <lpage>2045894018776496</lpage>
          <pub-id pub-id-type="doi">10.1177/2045894018776496</pub-id>
        </element-citation>
        <mixed-citation>2 Sato S, Ogawa A, Matsubara H. Change in R Wave in Lead V1 Predicts Survival of Patients with Pulmonary Arterial Hypertension. Pulm Circ. 2018;8(2):2045894018776496. doi: 10.1177/2045894018776496.</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagase</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kamakura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kataoka</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamagata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishibashi</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Low-Voltage Type 1 ECG is Associated with Fatal Ventricular Tachyarrhythmia in Brugada Syndrome</article-title>
          <source>J Am Heart Assoc</source>
          <year>2018</year>
          <volume>7</volume>
          <issue>21</issue>
          <elocation-id>e009713</elocation-id>
          <pub-id pub-id-type="doi">10.1161/JAHA.118.009713</pub-id>
        </element-citation>
        <mixed-citation>3 Nagase S, Kamakura T, Kataoka N, Wada M, Yamagata K, Ishibashi K, et al. Low-Voltage Type 1 ECG is Associated with Fatal Ventricular Tachyarrhythmia in Brugada Syndrome. J Am Heart Assoc. 2018;7(21):e009713. doi: 10.1161/JAHA.118.009713.</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aldred</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Morrell</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Guignabert</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis</article-title>
          <source>Circ Res</source>
          <year>2022</year>
          <volume>130</volume>
          <issue>9</issue>
          <fpage>1365</fpage>
          <lpage>1381</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.320084</pub-id>
        </element-citation>
        <mixed-citation>4 Aldred MA, Morrell NW, Guignabert C. New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis. Circ Res. 2022;130(9):1365-81. doi: 10.1161/CIRCRESAHA.122.320084.</mixed-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="S1" xml:lang="en">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abc.20250159i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>How to Assess Impaired Right Heart Electrical Conduction in Patients with Pulmonary Arterial Hypertension?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kataoka</surname>
            <given-names>Naoya</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-7294-7637</contrib-id>
          <name>
            <surname>Imamura</surname>
            <given-names>Teruhiko</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
        <aff id="aff2">
          <label>1</label>
          <addr-line>
            <named-content content-type="city">Toyama</named-content>
          </addr-line>
          <country country="JP">Japan</country>
          <institution content-type="original">Segundo Departamento de Medicina Interna, Universidade de Toyama, Toyama &#8211; Japan</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c2"><label>Mailing Address:</label><bold>Teruhiko Imamura &#8226;</bold> Second Department of Internal Medicine, University of Toyama, 2630, Sugitani Toyama, <postal-code>930-0194</postal-code> &#8211; Japan E-mail: <email>te.imamu@gmail.com</email></corresp>
      </author-notes>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Electrocardiography</kwd>
        <kwd>Heart Failure</kwd>
        <kwd>Bundle-Branch Block</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>To editor</bold>
      </p>
      <p>The identification of an optimal modality to monitor the severity of pulmonary arterial hypertension (PAH) remains imperative. The authors demonstrated that a prolonged RS interval on the electrocardiogram was associated with adverse clinical outcomes in this cohort, under the hypothesis that right heart electrical conduction is compromised in patients with severe PAH.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Nonetheless, several concerns merit consideration.</p>
      <p>The RS interval was measured at inferolateral leads, specifically V5 and V6.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> However, right ventricular information is conventionally derived from right precordial leads, such as V1 and V2. In cases of right bundle branch block, a prominent S wave in the inferolateral leads is a characteristic feature. A prolonged RS interval at these leads may reflect a dominant R wave in the right precordial leads. Previous studies have identified an elevated R wave amplitude in lead V1 as a prognostic marker in PAH patients.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Comparable observations have been made in Brugada syndrome, where right ventricular dysfunction predominates.<sup><xref ref-type="bibr" rid="B3">3</xref></sup> The incorporation of the right precordial lead characteristics could enhance the robustness of the authors&#8217; findings.</p>
      <p>Additionally, the longitudinal behavior of the RS interval, particularly its trajectory in response to reductions in pulmonary artery pressure during therapeutic interventions, warrants further exploration.</p>
      <p>Potential confounders not accounted for in the analysis may have influenced the results. Given the extended study duration spanning from 2010 to 2022,<sup><xref ref-type="bibr" rid="B1">1</xref></sup> the therapeutic landscape for PAH likely evolved, with shifts in medication regimens. Moreover, patient responses to treatment are significantly modulated by genetic factors, such as mutations in the BMPR2 gene.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Addressing these variables may provide a more comprehensive understanding of the relationship between RS interval prolongation and clinical outcomes in PAH.</p>
    </body>
  </sub-article>
</article>
